Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy
and
Feb 21, 2018
About this article
Article Category: Research Article
Published Online: Feb 21, 2018
Page range: 281 - 288
Received: Nov 22, 2017
Accepted: Nov 30, 2017
DOI: https://doi.org/10.2478/raon-2018-0009
Keywords
© 2018 Martina Vrankar, Karmen Stanic, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Figure 2
Median overall survival (OS) according to PD-L1 status
| PD-L1 negative or unknown N = 95 | PD-L1 expression N = 7 | |
|---|---|---|
| Median OS (months) | 25.2 | 12.1 |
| 1-year OS (%) | 77.9 | 57.1 |
| 2-year OS (%) | 54.7 | 14.3 |
| 3-year OS (%) | 40.0 | 14.3 |
| 4-year OS (%) | 28.4 | 14.3 |
| 5-year OS (%) | 24.2 | 0 |
| 10-year OS (%) | 12.1 | 0 |
Treatment-related toxicities of induction chemotherapy with regard to PD-L1 status
| PD-L1 negative or unknown N = 95 (%) | PD-L1 expression N = 7 (%) | p | |
|---|---|---|---|
| Anaemia | |||
| Grade 1, 2 | 87 (91.6) | 6 (85.7) | 0.780 |
| Grade 3, 4 | 1 (1.1) | 0 | |
| Neutropenia | |||
| Grade 1, 2 | 24 (25.5) | 0 | 0.168 |
| Grade 3, 4 | 23 (24.2) | 1 (14.3) | |
| Thrombocytopenia | |||
| Grade 1, 2 | 23 (24.5) | 1 (14.3) | 0.001 |
| Grade 3, 4 | 0 | 1 (14.3) | |
| Acute kidney injury | |||
| Grade 1, 2 | 30 (31.6) | 5 (71.4) | 0.045 |
| Grade 3, 4 | 0 | 0 | |
| Nausea/vomiting | |||
| Grade 1, 2 | 34 (35.8) | 5 (71.4) | 0.167 |
| Grade 3, 4 | 4 (4.3) | 0 |
Treatment-related toxicities of concurrent chemoradiotherapy (CCRT) with regard to PD-L1 status
| PD-L1 negative or unknown N = 94 (%) | PD-L1 expression N = 7 (%) | p | ||
|---|---|---|---|---|
| Anemia | Grade 1, 2 | 91 (95.8) | 6 (85.7) | 0.001 |
| Grade 3, 4 | 4 (4.3) | 0 | ||
| Neutropenia | Grade 1, 2 | 27 (28.7) | 2 (28.6) | 0.171 |
| Grade 3, 4 | 29 (30.5) | 0 | ||
| Thrombocytopenia | Grade 1, 2 | 48 (50.5) | 2 (28.6) | 0.357 |
| Grade 3, 4 | 5 (5.3) | 0 | ||
| Acute kidney injury | Grade 1, 2 | 35 (36.8) | 4 (57.1) | 0.250 |
| Grade 3, 4 | 0 | 0 | ||
| Nausea/vomiting | Grade 1, 2 | 16 (17.0) | 0 | 0.041 |
| Grade 3, 4 | 5 (5.3) | 2 (28.6) | ||
| Esophagitis | Grade 1, 2 | 63 (67.0) | 4 (57.1) | 0.500 |
| Grade 3, 4 | 12 (12.8) | 2 (28.6) | ||
| Pneumonitis | Grade 1, 2 | 5 (5.3) | 0 | 0.294 |
| Grade 3, 4 | 3 (3.2) | 1 (14.3) |
Patients characteristics according to PD-L1 expression
| PD-L1 negative or unknown (N = 95) | PD-L1 expression (N = 7) | Total (N = 102) | |
|---|---|---|---|
| Gender | |||
| Male | 74 | 6 | 80 |
| Female | 21 | 1 | 22 |
| Age | |||
| Median | 57 | 59 | 57 |
| Range | 30–77 | 54–64 | 30–77 |
| ECOG PS | |||
| 0 | 82 | 7 | 89 |
| 1 | 13 | 0 | 13 |
| Histology | |||
| Squamous | 53 | 6 | 59 |
| Adeno | 23 | 0 | 23 |
| Large cell | 6 | 0 | 6 |
| Other & unspecifie | 13 | 1 | 14 |
| Stage | |||
| IIIA | 54 | 4 | 58 |
| IIIB | 41 | 3 | 44 |
| Inoperable due to | |||
| Extent | 93 | 7 | 100 |
| Functional | 1 | 0 | 1 |
| Refuse | 1 | 0 | 1 |